Phase II Trial in AChR Ab+ Myasthenia Gravis of Transition from Intravenous to Subcutaneous Immunoglobulin: The MGSCIg Study.

Mamatha PasnoorVera BrilTodd LevineJaya TrivediNicholas J SilvestriMilind PhadnisHans D KatzbergDavid S SapersteinGil I WolfeLaura HerbelinKiley HiggsAndrew J HeimJeffrey M StatlandRichard J BarohnMazen M Dimachkie

Published in: European journal of neurology (2023)

MG patients on IVIg as part of their routine clinical care remained stable on monthly IVIg dosage, and most maintained similar disease stability on SCIg.

Keyphrases

myasthenia gravis
end stage renal disease
ejection fraction
healthcare
chronic kidney disease
newly diagnosed
randomized controlled trial
peritoneal dialysis
quality improvement
patient reported outcomes
affordable care act
double blind